Humberto C. Antunes, Galderma’s worldwide CEO, will receive a "Lifetime in Dermatology Achievement Award" from the Journal of Drugs in Dermatology at the upcoming Orlando Dermatology Aesthetic & Clinical Conference (ODAC), which begins Friday in Orlando.
The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication founded by Perry Robins, MD.
In 2013, the JDD requested nominations from the entire dermatology community, including the JDD editorial board, authors, and reviewers, for those companies regarded among their peers as the very best thought leaders in a particular dermatology specialty.
Galderma was elected to receive the prestigious JDD Leaders of Distinction Award and chosen as the Leader of Distinction for the "Lifetime in Dermatology Achievement Award."
"Galderma is one of the world's leading pharmaceutical companies in dermatology, and also one of the most generous, much of which would not be possible without Humberto Antunes' leadership, dedication and philanthropy to the industry," said Dr. Robins, ODAC Conference Chair Emeritus and Professor Emeritus of Dermatology at New York University School of Medicine.
"I have had the pleasure of knowing Humberto for many, many years and in that vein, it gives me great pleasure to honor him with the Journal of Drugs in Dermatology 'Lifetime in Dermatology Achievement Award,' and know that he will continue to positively shape the future of dermatology," added Dr. Robins.
Antunes is set to accept the honor person at the ODAC meeting on Jan. 17, where is he slated to deliver a key note address, "Future of Dermatology.”
Galderma is a joint-venture between Nestle and L'Oréal, founded in 1981. Cetaphil is the brand's best known OTC skin care line.